...
首页> 外文期刊>Cardiology >Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease.
【24h】

Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease.

机译:小儿患者的围手术期肺动脉高压:先天性心脏病患儿的当前策略。

获取原文
获取原文并翻译 | 示例
           

摘要

Congenital heart disease (CHD) is responsible for pulmonary hypertension (PH) in children in about 50% of cases. This pre-operative dynamic pulmonary hypertension can be superimposed and aggravated by acute post-operative PH or persist as chronic PH, especially in children who are not operated on early enough. Inhaled iloprost, a stable prostacyclin analogue, is used for the post-operative management of PH in infants and children with CHD. In a prospective open-label proof-of-concept study, the efficacies of inhaled nitric oxide (iNO) and inhaled iloprost were directly compared. Primary endpoints were the occurrence of a major or minor pulmonary hypertensive crisis. No significant difference between the effects of iNO versus iloprost on peri-operative PH was observed. Neither substance on its own prevented pulmonary hypertensive crises in high-risk infants, so a combination of both substances should be tested in future trials. In China, there are more than 4 million untreated CHD patients. More than 50% of them are untreated adults. Acute pulmonary vasoreactivity tests were performed in CHD patients between 9 months and 43 years of age using inhaled iloprost, in order to find out whether a pre-operative response to inhaled iloprost is a good predictor for the post-operative performance of these patients. The results showed that patient selection criteria for surgery should include both a 20% reduction in pulmonary vascular resistance (PVR) index after iloprost inhalation and a resulting PVR index <11 Wood U/m(2). CHD children between 14 days and 11 years of age took part in a placebo-controlled pilot study that investigated the role of aerosolized iloprost in the treatment of PH after corrective surgery. They received either low- or high-dose iloprost or placebo. Inhaled iloprost significantly improved haemodynamics in a dose-dependent manner and prevented reactive PH and pulmonary hypertensive crises in most of these mechanically ventilated children after CHD repair.
机译:先天性心脏病(CHD)导致约50%的儿童患肺动脉高压(PH)。这种术前动态肺动脉高压可被急性术后PH叠加或加重,或持续为慢性PH,特别是对于未及早手术的儿童。吸入的伊洛前列素(一种稳定的前列环素类似物)可用于冠心病婴儿和儿童的PH术后管理。在一项前瞻性开放标签概念验证研究中,直接比较了吸入一氧化氮(iNO)和吸入伊洛前列素的疗效。主要终点是发生严重或轻微的肺动脉高压危机。观察到iNO与伊洛前列素对围手术期PH的影响之间没有显着差异。两种物质都不能单独预防高危婴儿的肺动脉高压危机,因此应在以后的试验中对两种物质的组合进行测试。在中国,有超过400万未经治疗的冠心病患者。其中超过50%是未经治疗的成年人。使用吸入伊洛前列素对9个月至43岁的CHD患者进行了急性肺血管反应性测试,以了解吸入伊洛前列素的术前反应是否是这些患者术后表现的良好预测指标。结果表明,患者的手术选择标准应包括吸入伊洛前列素后肺血管阻力(PVR)指数降低20%,以及所产生的PVR指数<11 Wood U / m(2)。 14天至11岁的冠心病儿童参加了安慰剂对照的初步研究,该研究调查了雾化伊洛前列素在矫正手术后在PH值治疗中的作用。他们接受了低剂量或高剂量伊洛前列素或安慰剂。吸入的伊洛前列素以剂量依赖性方式显着改善了血流动力学,并在大多数冠心病修复后的机械通气儿童中预防了反应性PH和肺动脉高压危机。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号